159 related articles for article (PubMed ID: 30606076)
1. Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy.
Li Q; Huang J; Ou Y; Li Y; Wu Y
Immunotherapy; 2019 Mar; 11(4):265-272. PubMed ID: 30606076
[TBL] [Abstract][Full Text] [Related]
2. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
3. Treatment of refractory diffuse large B-cell lymphoma by chidamide combined with autologous stem cell transplantation: a case report.
Wu P; Ma T; Chen Y; Wang F; Chen Y; Gao J; Zhou Z; Jia Y
Anticancer Drugs; 2021 Sep; 32(8):886-889. PubMed ID: 34145178
[TBL] [Abstract][Full Text] [Related]
4. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
[TBL] [Abstract][Full Text] [Related]
5. Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report.
Yang D; Zhang WP; Yang JM; He MX; Cheng C; Chen J
Medicine (Baltimore); 2018 Dec; 97(49):e13093. PubMed ID: 30544372
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
Luo C; Yu T; Young KH; Yu L
J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
[TBL] [Abstract][Full Text] [Related]
7. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.
Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
[TBL] [Abstract][Full Text] [Related]
8. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of relapsed and refractory EZB/C3 subtype DLBCL with chidamide in combination of R2-CHOP: a case report].
Yang L; Zhang W; Zhang ML; Shen KF; Wang JC; Guan YQ; Cai HD; Bao YH; Xiao M; Zhou JF; Zheng M
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):436-437. PubMed ID: 34218590
[No Abstract] [Full Text] [Related]
10. Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Hayashi K; Nagasaki E; Kan S; Ito M; Kamata Y; Homma S; Aiba K
Cancer Sci; 2016 May; 107(5):682-9. PubMed ID: 26920337
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
[TBL] [Abstract][Full Text] [Related]
12. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
[No Abstract] [Full Text] [Related]
13. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
[TBL] [Abstract][Full Text] [Related]
15. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
16. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
Liu Y; Wang X; Ding N; Mi L; Ping L; Jin X; Li J; Xie Y; Ying Z; Liu W; Zhang C; Deng L; Song Y; Zhu J
BMC Cancer; 2017 Nov; 17(1):743. PubMed ID: 29126407
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutation and survival in aggressive B cell lymphoma.
Zenz T; Kreuz M; Fuge M; Klapper W; Horn H; Staiger AM; Winter D; Helfrich H; Huellein J; Hansmann ML; Stein H; Feller A; Möller P; Schmitz N; Trümper L; Loeffler M; Siebert R; Rosenwald A; Ott G; Pfreundschuh M; Stilgenbauer S;
Int J Cancer; 2017 Oct; 141(7):1381-1388. PubMed ID: 28614910
[TBL] [Abstract][Full Text] [Related]
18. Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.
Kazantseva M; Hung NA; Mehta S; Roth I; Eiholzer R; Rich AM; Seo B; Baird MA; Braithwaite AW; Slatter TL
Sci Rep; 2017 May; 7(1):1566. PubMed ID: 28484276
[TBL] [Abstract][Full Text] [Related]
19. Targeting HDACs for diffuse large B-cell lymphoma therapy.
Wu C; Song Q; Gao S; Wu S
Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
[TBL] [Abstract][Full Text] [Related]
20. Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?
Asmar F; Hother C; Kulosman G; Treppendahl MB; Nielsen HM; Ralfkiaer U; Pedersen A; Møller MB; Ralfkiaer E; de Nully Brown P; Grønbæk K
Oncotarget; 2014 Apr; 5(7):1912-25. PubMed ID: 24722400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]